U.S. Markets closed

Minerva Neurosciences shares rise 5% on trial results for schizophrenia drug

Emma Court

Minerva Neurosciences Inc. shares rose 5.4% in premarket trade on Thursday after results from a phase 2b trial for a schizophrenia drug were published in the peer-reviewed The Journal of Clinical Psychiatry. Patients on the therapy, roluperidone, showed cognitive improvements; the cognitive improvements were also connected to previously-reported improvements in negative symptoms, the company said. Minerva shares have surged 19.3% over the last three months, compared with a 0.4% decline in the S&P 500 and a 1.8% drop in the Dow Jones Industrial Average .





More From MarketWatch